East Asia Pharmaceutical (605177.SH) released its first three quarters performance, with a net loss attributable to shareholders of RMB 197 million.

Zhitong Finance APP News, East Asia Pharmaceutical (605177.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 609 million yuan, a year-on-year increase of 2.12%; net profit attributable to shareholders of the listed company recorded a loss of 197 million yuan, and net profit after deducting non-recurring gains and losses recorded a loss of 207 million yuan; basic earnings per share was -1.72 yuan.